Search
Azetukalner
go.drugbank.com/drugs/DB21551InvestigationalAzetukalner is a small molecule drug. The usage of the INN stem '-kalner' in the name indicates that Azetukalner is a opener of calcium-activated (maxi-K) K+-channel. … Azetukalner is under investigation in clinical trial NCT05718817 (An Open-label Study of XEN1101 in Epilepsy). Azetukalner has a monoisotopic molecular weight of 368.23 Da.
Polaprezinc
go.drugbank.com/drugs/DB09221InvestigationalPolaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308]. … A study in 2013 showed that CO-administration of polaprezinc may be effective against small intestine mucosal injury associated with long-term aspirin therapy [A7840].
J147
go.drugbank.com/drugs/DB13957Experimental[A31606,A31607,A31608] It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging … J147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesTaspoglutide
go.drugbank.com/drugs/DB14027InvestigationalAs of May 2013 no new trials had been registered. … Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.
Adlinacogene civaparvovec
go.drugbank.com/drugs/DB16788InvestigationalAdlinacogene civaparvovec is an investigational _in vivo_ genome editing therapeutic product. … It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX.
AZD7442
go.drugbank.com/drugs/DB15787Investigational[L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591] … AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19.
CIGB 2020 Vaccine
go.drugbank.com/drugs/DB15808ExperimentalAs of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate prophylaxis potential in suspected contacts of Covid-19 patients. … CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered.
Peginterferon alfacon-1
go.drugbank.com/drugs/DB05860ExperimentalPEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small … [Infergen] is a bio-engineered type I interferon alpha that is FDA-approved for the treatment of patients with chronic hepatitis C infections.
1alpha,24S-Dihydroxyvitamin D2
go.drugbank.com/drugs/DB06117ExperimentalStudies have shown LR-103 has the same potency as calcitriol, but much lower toxicity. … LR-103 is a naturally occurring D-hormone that is produced by the kidneys from vitamin D. LR-103 is one of the D-hormones produced from Hectorol.
JB991
go.drugbank.com/drugs/DB05081ExperimentalJB991 is a cyclopentenone prostaglandin analogue intended for treatment of psoriasis. … In addition a closely related cyclopentenone prostaglandin analogue has been shown to exert marked anti-inflammatory effect in vivo in an animal model. The drug will be applied topically on the skin.